Literature DB >> 15760722

Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.

Dirk Lochmann1, Jörg Weyermann, Christiane Georgens, Ruth Prassl, Andreas Zimmer.   

Abstract

In this paper, a ternary system of albumin-protamine-oligonucleotide nanoparticles (AlPrO-NP) recently developed by Vogel et al. [V. Vogel, D. Lochmann, J. Weyermann, G. Mayer, C. Tziatzios, J.A. van den Broek, W. Haase, D. Wouters, U.S. Schubert, J. Kreuter, A. Zimmer, D. Schubert, Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties and intracellular processing, J. Controlled Rel. (in press)] which could serve as a potential drug delivery system for antisense oligonucleotides. Former studies of binary protamine-oligonucleotide nanoparticles showed two main disadvantages: (i) aggregation of the particles within a few minutes in the presence of salt; (ii) low intracellular dissociation between protamine and oligonucleotide, especially phosphorothioates. To overcome these problems, human serum albumin (HSA) as a non-toxic, biodegradable macromolecule was introduced as protective colloid. The assembly process of AlPrO-NP was investigated by small angle X-ray scattering (SAXS), fluorescence correlation spectroscopy (FCS), photon correlation spectroscopy (PCS) measurements and scanning electron microscopy (SEM). 'Initial complexes' of HSA and protamine sulphate with a mean hydrodynamic diameter (dh) of about 10-14 nm were found. After adding oligonucleotides (unmodified, phosphorothioate DNA and small interfering RNA), nanoparticles (NPs) were assembled in water and in isotonic media with a dh in a range of 230-320 nm for most preparations. The chemical composition of the particles was investigated by high performance liquid chromatography and fluorescence spectrometry. The whole amount of oligonucleotides (30 microg) was entrapped into the particles at a 1:2 mass ratio (oligonucleotide/protamine). Approximately 7-10% (w/w) of the HSA was bound to the particles. The surface charge of the particles ranged from about +12 to -60 mV depending on the protamine concentration and the ionic conditions. The size and the molecular weight of the components, initial complexes and two model NP preparations were calculated from FCS data. These data verified the PCS, SEM and SAXS measurements.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15760722     DOI: 10.1016/j.ejpb.2004.04.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  18 in total

Review 1.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

Review 2.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

3.  Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.

Authors:  Meng-Qing Gong; Cong Wu; Xiao-Yan He; Jing-Yi Zong; Jin-Long Wu; Ren-Xi Zhuo; Si-Xue Cheng
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

4.  Nanoencapsulation of synergistic combinations of acai berry concentrate to improve antioxidant stability.

Authors:  Hee Ryung Shim; Ji-Soo Lee; Hee Sop Nam; Hyeon Gyu Lee
Journal:  Food Sci Biotechnol       Date:  2016-12-31       Impact factor: 2.391

Review 5.  Encapsulation of nucleic acids and opportunities for cancer treatment.

Authors:  Lisa Brannon-Peppas; Bilal Ghosn; Krishnendu Roy; Kenneth Cornetta
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

6.  Constitutive expression Of NGF And P75(NTR) affected by bladder distension and NGF antisense treatment.

Authors:  Mahendra Kashyap; Subrata Pore; Naoki Yoshimura; Pradeep Tyagi
Journal:  Life Sci       Date:  2016-02-05       Impact factor: 5.037

7.  Accelerated stem cell labeling with ferucarbotran and protamine.

Authors:  Daniel M Golovko; Tobias Henning; Jan S Bauer; Marcus Settles; Thomas Frenzel; Artur Mayerhofer; Ernst J Rummeny; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2009-09-12       Impact factor: 5.315

8.  Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier.

Authors:  Ingrid Kratzer; Karin Wernig; Ute Panzenboeck; Eva Bernhart; Helga Reicher; Robert Wronski; Manfred Windisch; Astrid Hammer; Ernst Malle; Andreas Zimmer; Wolfgang Sattler
Journal:  J Control Release       Date:  2006-11-28       Impact factor: 9.776

9.  An efficient targeted drug delivery through apotransferrin loaded nanoparticles.

Authors:  Athuluri Divakar Sai Krishna; Raj Kumar Mandraju; Golla Kishore; Anand Kumar Kondapi
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

Review 10.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.